Evotec (NASDAQ:EVO) Shares Gap Up - Should You Buy?

Key Points

• Evotec shares gapped up, opening at $3.06 after a $2.78 close and last trading around $3.08 on a volume of about 29,600 shares.
• Analyst coverage is mixed—three Buys, one Hold and one Sell—resulting in an average rating of Hold and a consensus target price of $7.00.
• Fundamentals show a recent quarter with $0.05 EPS and $297.02M revenue but a negative net margin (-13.13%) and ROE (-12.40%), and analysts project -0.41 EPS for the current year.

Evotec AG (NASDAQ:EVO - Get Free Report) shares gapped up before the market opened on Tuesday . The stock had previously closed at $2.78, but opened at $3.06. Evotec shares last traded at $3.0750, with a volume of 29,601 shares traded.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on EVO shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Evotec in a research report on Monday, December 29th. Wall Street Zen raised shares of Evotec from a "sell" rating to a "hold" rating in a research report on Saturday, January 10th. Finally, Berenberg Bank started coverage on shares of Evotec in a research report on Tuesday, February 3rd. They set a "buy" rating on the stock. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Evotec currently has an average rating of "Hold" and a consensus target price of $7.00.

Evotec Stock Performance

The stock's 50 day moving average is $2.97 and its two-hundred day moving average is $3.29. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.99 and a current ratio of 2.07.

Evotec (NASDAQ:EVO - Get Free Report) last released its earnings results on Tuesday, March 31st. The company reported $0.05 earnings per share for the quarter. Evotec had a negative net margin of 13.13% and a negative return on equity of 12.40%. The firm had revenue of $297.02 million for the quarter. Analysts anticipate that Evotec AG will post -0.41 EPS for the current year.

Institutional Trading of Evotec

A number of large investors have recently made changes to their positions in the company. XTX Topco Ltd increased its stake in shares of Evotec by 25.1% during the fourth quarter. XTX Topco Ltd now owns 18,469 shares of the company's stock worth $57,000 after buying an additional 3,709 shares during the period. Wellington Management Group LLP increased its stake in shares of Evotec by 25.7% during the fourth quarter. Wellington Management Group LLP now owns 1,797,444 shares of the company's stock worth $5,536,000 after buying an additional 367,545 shares during the period. OLD Mission Capital LLC purchased a new stake in shares of Evotec during the fourth quarter worth approximately $158,000. Millennium Management LLC purchased a new stake in shares of Evotec during the fourth quarter worth approximately $317,000. Finally, Marshall Wace LLP purchased a new stake in shares of Evotec during the fourth quarter worth approximately $40,000. 5.81% of the stock is currently owned by hedge funds and other institutional investors.

Evotec Company Profile

Evotec SE NASDAQ: EVO is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec's service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.